Construction of an aptamer modified liposomal system targeted to tumor endothelial cells

Biological and Pharmaceutical Bulletin

Volumn 37, Issue 11, 2014, Pages 1742-1749

  Ara, Mst Naznin ^a   Matsuda, Takashi ^a   Hyodo, Mamoru ^a   Sakurai, Yu ^a   Ohga, Noritaka ^a   Hida, Kyoko ^a   Harashima, Hideyoshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Aptamer based liposome; Cell based systematic evolution of ligands by exponential enrichment; Heat shock protein 70 (HSP70); Targeted drug delivery; Tumor endothelial cell

Indexed keywords

APTAMER; ARAHH036 APTAMER; HEAT SHOCK PROTEIN 70; LIPOSOME; MACROGOL 2000; MALEIMIDE; RHODAMINE; UNCLASSIFIED DRUG; 1,2-DISTEAROYLPHOSPHATIDYLETHANOLAMINE; MACROGOL DERIVATIVE; MALEIMIDE DERIVATIVE; NANOPARTICLE; PHOSPHATIDYLETHANOLAMINE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELLULAR DISTRIBUTION; CHEMICAL BINDING; CONFOCAL LASER SCANNING MICROSCOPE; CONJUGATION; CONTROLLED STUDY; ENDOTHELIUM CELL; HYDRATION; INTERNALIZATION; INTRACELLULAR TRANSPORT; LIPID HYDRATION; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PROTEIN TARGETING; TUMOR CELL; TUMOR VASCULARIZATION; 3T3 CELL LINE; ANIMAL; CELL CULTURE; CHEMISTRY; CYTOLOGY; HUMAN; LYSOSOME; METABOLISM; NEOPLASM; NUDE MOUSE; PROTEOMICS; SKIN; TUMOR CELL LINE;

ANIMALS; APTAMERS, NUCLEOTIDE; CELL LINE, TUMOR; CELLS, CULTURED; ENDOTHELIAL CELLS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; LIPOSOMES; LYSOSOMES; MALEIMIDES; MICE; MICE, NUDE; NANOPARTICLES; NEOPLASMS; NIH 3T3 CELLS; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; PROTEOMICS; SKIN;

EID: 84910077108     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b14-00338     Document Type: Article

References (31)

1. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature, 438, 967-974 (2005).
2. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat. Rev. Cancer, 6, 449-458 (2006).
3. Weigelt B, Peterse JL, van't Veer LJ. Cancer metastasis: Markers and models. Nat. Rev. Cancer, 5, 591-602 (2005).
4. Folkman J. Angiogenesis, an organizing principle for drug discovery? Nat. Rev. Drug Discov., 6, 273-286 (2007).
5. Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int. J. Nanomedicine, 7, 49-60 (2012).
6. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim. Biophys. Acta, 1113, 171-199 (1992).
7. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. U.S.A., 85, 6949-6953 (1988).
8. Gabizon A, Martin F. Polyethylene glycol-coated (PEGylated) liposomal doxorubicin. Drugs, 54 (Suppl. 4), 15-21 (1997).
9. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature, 346, 818-822 (1990).
10. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment, RNA ligands to bacteriophage T4 DNA polymerase. Science, 249, 505-510 (1990).
11. Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, Mallikaratchy P, Sefah K, Yang CJ, Tan W. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl. Acad. Sci. U.S.A., 103, 11838-11843 (2006).
12. Cullen BR, Greene WC. Regulatory pathways governing HIV-1 replication. Cell, 58, 423-426 (1989).
13. Tan W, Wang H, Chen Y, Zhang X, Zhu H, Yang C, Yang R, Liu C. Molecular aptamers for drug delivery. Trends Biotechnol., 29, 634-640 (2011).
14. Zhang Y, Hong H, Cai W. Tumor targeted drug delivery with aptamers. Curr. Med. Chem., 18, 4185-4194 (2011).
15. Zhou J, Rossi JJ. Cell-specific aptamer targeted drug delivery. Oligonucleotides, 21, 1-10 (2011).
16. Reinemann CS. Aptamer-modified nanoparticle and their use in cancer diagnostic and treatment. Swiss Med. Wkly., 144, 1-12 (2014).
17. Burdick MM, McCarty OJT, Jadhav S, Konstantopoulos K. Cell-cell interactions in inflammation and cancer metastasis. IEEE Eng. Med. Biol. Mag., 20, 86-91 (2001).
18. Siegel G, Malmsten M. The role of the endothelium in inflammation and tumor metastasis. Int. J. Microcirc. Clin. Exp., 17, 257-272 (1997).
19. Hida K, Klagsbrun M. A new perspective on tumor endothelial cells, unexpected chromosome and centrosome abnormalities. Cancer Res., 65, 2507-2510 (2005).
20. Hida K, Hida Y, Shindoh M. Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci., 99, 459-466 (2008).
21. Akino T, Hida K, Hida Y, Tsuchiya K, Freedman D, Muraki C, Ohga N, Matsuda K, Akiyama K, Harabayashi T, Shinohara N, Nonomura K, Klagsbrun M, Shindoh M. Cytogenic abnormalities of tumor-associated endothelial cells in human malignant tumors. Am. J. Pathol., 175, 2657-2667 (2009).
22. Matsuda K, Ohga N, Hida Y, Muraki C, Tsuchiya K, Kurosu T, Akino T, Shih S-C, Totsuka Y, Klagsbrun M, Shindoh M, Hida K. Isolated tumor endothelial cells maintain the specific character during long-term culture. Biochem. Biophys. Res. Commun., 394, 947-954 (2010).
23. Suzuki Y, Ohga N, Morishita Y, Hida K, Miyazono K, Watabe T. BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo. J. Cell Sci., 123, 1684-1692 (2010).
24. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv. Drug Deliv. Rev., 65, 36-48 (2013).
25. Ara MN, Hyodo M, Ohga N, Hida K, Harashima H. Development of a novel DNA aptamer ligand targeting to primary cultured tumor endothelial cells by a cell-based SELEX method. PLoS ONE, 7, e50174 (2012).
26. Nallamothu R, Wood GC, Pattillo CB, Scott RC, Kiani MF, Moore BM, Thoma L. A tumor vasculature targeted liposome delivery system for Combretastin A4: Design, characterization, and in vitro evaluation. AAPS PharmSciTech, 7, E7-E16 (2006).
27. Akhter A, Hayashi Y, Sakurai Y, Ohga N, Hida K, Harashima H. A liposomal delivery system that targets liver endothelial cells based on a new peptide motif present in the ApoB-100 sequence. Int. J. Pharm., 456, 195-201 (2013).
28. Murphy ME. The HSP70 family and cancer. Carcinogenesis, 34, 1181-1188 (2013).
29. Bayer C, Liebhardt ME, Schmid TE, Trajkovic-Arsic M, Hube K, Specht HM, Schilling D, Gehrmann M, Stangl S, Siveke JT, Wilkens JJ, Multhoff G. Validation of a heat shock protein 70 as a tumor specific biomarker for monitoring the outcome of radiation therapy in tumor mouse models. Int. J. Radiat. Oncol. Biol. Phys., 88, 694-700 (2014).
30. Multhoff G, Hightower LE. Distinguishing integral and receptor-bound heat shock protein 70 (Hsp 70) on the cell surface by Hsp70 specific antibody. Cell Stress Chaperones, 16, 251-255 (2011).
31. Stangl S, Ghermann M, Riegger J, Kuhs K, Riederer I, Sievert W, Hube K, Mocikat R, Dressel R, Kremmer E, Pockley AG, Friedrich L, Vigh L, Skerra A, Multhoff G. Targeting membrane heat-shock protein 70 (Hsp 70) on tumors by cmHsp 70.1 antibody. Proc. Natl. Acad. Sci. U.S.A., 108 , 733-738 (2011).